A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer Patients

This study tests various combinations of investigational drugs — including HRS-2189, HRS-6209, HRS-8080, and HRS-1358 — in women with advanced or metastatic breast cancer whose cancer progressed after hormone therapy with or without CDK4/6 inhibitor drugs. **You may be eligible if...** - You have advanced (unresectable) or metastatic breast cancer confirmed by biopsy - Your cancer progressed after prior endocrine (hormone) therapy, with or without CDK4/6 inhibitors - You are postmenopausal (or premenopausal with ovarian suppression) - Your overall health meets the required performance status (ECOG 0–1) **You may NOT be eligible if...** - Your cancer is triple-negative (hormone-receptor negative, HER2-negative) - You have uncontrolled brain metastases - You have severe organ dysfunction - You are pregnant or breastfeeding - You have active serious infections or significant other medical conditions Talk to your doctor to see if this trial is right for you.